Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2025-01-24 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第四届监事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Shanghai Medicilon Inc. It details the meeting date, attendance, and the approval of a proposal regarding the postponement of certain fundraising investment projects. It references compliance with Chinese securities regulations and confirms no adverse impact on shareholders. The document is short (764 characters) and does not contain financial statements or detailed financial data. It is an announcement of a board/management decision rather than a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG).
2025-01-24 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司部分募投项目延期的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Guangfa Securities) regarding the delay in certain fundraising investment projects of Shanghai Medicilon Inc. It references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange rules, discusses the use and management of raised funds, project progress, reasons for delay, and the sponsor's conclusion that the delay complies with relevant laws and regulations. The document is not a full annual or interim financial report, nor is it an earnings release or a call transcript. It is not a proxy statement or voting result announcement. It is a regulatory compliance and verification report related to fundraising project progress and use of proceeds. The document length is under 5,000 characters and it is a formal opinion/report from the sponsor on a specific regulatory matter. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2025-01-24 Chinese
美迪西：关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the delay of certain projects funded by proceeds from a specific share issuance. It details the background of the fundraising, the investment projects, the reasons for the delay, and confirms that the delay does not change the use or amount of the funds. It includes references to regulatory approvals and compliance with stock exchange rules. The document is relatively short (3974 characters) and primarily serves as a formal announcement about the postponement of project milestones related to previously raised capital. It does not contain full financial statements or detailed financial performance data. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or similar. It is not a report publication announcement since it contains substantive information about the project delay itself. The content fits best with a Capital/Financing Update (CAP) as it relates to the use and timing of capital raised through a share issuance and the progress of funded projects.
2025-01-24 Chinese
美迪西：关于以集中竞价方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Shanghai Medicilon Inc. regarding a share repurchase plan. It includes specifics about the repurchase amount, funding sources, purposes (such as employee stock plans and capital reduction), pricing, procedures, authorizations, and risk disclosures. The text repeatedly references the company's board and shareholder meetings approving the repurchase plan and outlines the implementation timeline and conditions. There are no financial statements or earnings data presented, nor is this a transcript or a report on legal proceedings or management changes. The document is not a report publication announcement but a substantive disclosure about the company's share buyback program. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about share repurchases. The document length and detail confirm it is not a brief notice but a full announcement of the repurchase plan.
2025-01-24 Chinese
美迪西：2024年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast (业绩预告) from Shanghai Medicilon Inc., providing preliminary estimated net profit and loss figures for the full fiscal year 2024. It explicitly states that the forecast is unaudited and based on preliminary calculations by the finance department. The document includes expected net profit ranges, comparisons to the prior year, reasons for performance changes, and risk warnings. It does not contain actual audited financial statements or comprehensive financial data, but rather a forecast or preliminary earnings guidance. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal period, even though it is a forecast rather than final results. The document length is short (1350 characters), but it is not merely an announcement of a report publication; it contains substantive financial estimates and analysis. Therefore, the best fitting category is Earnings Release (ER). FY 2024
2025-01-17 Chinese
美迪西：第四届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the first meeting of the fourth Supervisory Board of Shanghai Medicilon Inc. It details the election of the Supervisory Board Chairman and confirms the legality and attendance of the meeting. It references another announcement for related board and management appointments. The content focuses on board/management changes and election results rather than financial data or report publication. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a report publication announcement.
2025-01-13 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.